Clinical trial
A Phase I/II Dose Escalation Trial Of HDAC Inhibitor Tefinostat (CHR2845) For Cancer Associated Inflammation In Hepatocellular Carcinoma
Phase I:
To determine the safety, tolerability and dose-limiting toxicities (DLT) of tefinostat when administered orally to patients with advanced HCC
To determine the recommended Phase II dose (RP2D) of tefinostat in patients with advanced HCC
Phase II:
To perform a preliminary assessment of the anti-disease activity of tefinostat as measured by mRECIST.
| Category | Value |
|---|---|
| Study start date | 2012-05-11 |